Hospital for Sick Children, 8253, Burton Wing, 555 University Avenue, Toronto, ON, M5G 1X8, Canada.
Pediatric Rheumatology, SRCC Children's Hospital, 1-1A, Keshavrao Khadye Marg, Haji Ali, Haji Ali Government Colony, Mahalakshmi, Mumbai, Maharashtra, 400034, India.
Pediatr Rheumatol Online J. 2020 Oct 17;18(1):81. doi: 10.1186/s12969-020-00475-0.
Intraarticular injections (IAI) were first reported in adult rheumatology in the 1950s and subsequently gained acceptance as a safe and efficacious treatment in Juvenile idiopathic arthritis (JIA). IAIs are now widely performed and recommended as the initial or only treatment of oligoarticular JIA and ancillary treatment of actively inflamed joints in other varieties of JIA. However, the performance of the procedure is currently not guided by standardized recommendations, and several practice variations are observed.
This worldwide survey of pediatric rheumatologists (with 48.5% response from Pediatric Rheumatology International Trials Organization [PRINTO and Pediatric Rheumatology Collaborative Study Group [PRCSG] members) captures the differences in pre-procedural, procedural and post-procedural protocols and practices observed across the globe and asks the necessity of developing consensus in this area of Pediatric Rheumatology.
This worldwide survey of Pediatric Rheumatologists had a response rate of just under 50% and the views of about 42% who routinely performed the procedure. It captured the differences in IAI protocols and practices observed across the globe. Significant variations in practice were noted in use of Local anesthesia, choice, and dose of therapeutic agent for the intraarticular injection and use of ultrasound to guide injections. While some practice variations may be explained by institutional protocols in different parts of the world, the clinical implications of these are largely unknown and beg the need for further studies.
Given these practice variations, the authors recommend further studies to explore the cost and clinical implications and subsequently work towards developing consensus plans to ensure uniformity in this widely used procedure in Pediatric Rheumatology.
关节内注射(IAI)于 20 世纪 50 年代首次在成人风湿病学中报道,随后作为一种安全有效的治疗方法在幼年特发性关节炎(JIA)中得到认可。IAI 现在被广泛应用,并被推荐作为寡关节炎 JIA 的初始或唯一治疗方法,以及其他 JIA 类型中活跃炎症关节的辅助治疗方法。然而,目前该操作的实施并非基于标准化建议,而是存在多种实践差异。
这项针对儿科风湿病学家的全球调查(来自儿科风湿病学国际试验组织 [PRINTO] 和儿科风湿病学协作研究组 [PRCSG] 成员的回应率为 48.5%)捕捉了全球范围内观察到的术前、术中和术后方案和实践的差异,并询问在儿科风湿病学领域是否有必要制定共识。
这项针对儿科风湿病学家的全球调查回应率略低于 50%,约有 42%的常规实施该操作的医生表达了观点。它捕捉到了全球范围内 IAI 方案和实践的差异。在局部麻醉的使用、关节内注射治疗药物的选择和剂量以及使用超声引导注射方面,存在显著的实践差异。虽然在世界不同地区的机构方案中可以解释一些实践差异,但这些差异的临床意义在很大程度上尚不清楚,需要进一步研究。
鉴于这些实践差异,作者建议进一步研究以探讨成本和临床意义,随后努力制定共识计划,以确保在儿科风湿病学中广泛使用的这一操作的一致性。